ATE316574T1 - Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen - Google Patents

Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen

Info

Publication number
ATE316574T1
ATE316574T1 AT98912541T AT98912541T ATE316574T1 AT E316574 T1 ATE316574 T1 AT E316574T1 AT 98912541 T AT98912541 T AT 98912541T AT 98912541 T AT98912541 T AT 98912541T AT E316574 T1 ATE316574 T1 AT E316574T1
Authority
AT
Austria
Prior art keywords
diagnosis
therapy
cancer
paraneoplastic neurological
neurological syndrome
Prior art date
Application number
AT98912541T
Other languages
English (en)
Inventor
Michele Aguera
Marie-Francoise Belin
Jerome Honnorat
Pappachan Kolattukudy
Than Tam Quach
Tamara Byk
Andre Sobel
Dominique Aunis
Jean-Christophe Antoine
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE316574T1 publication Critical patent/ATE316574T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98912541T 1997-02-19 1998-02-19 Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen ATE316574T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9701961A FR2759701B1 (fr) 1997-02-19 1997-02-19 Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques

Publications (1)

Publication Number Publication Date
ATE316574T1 true ATE316574T1 (de) 2006-02-15

Family

ID=9503917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912541T ATE316574T1 (de) 1997-02-19 1998-02-19 Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen

Country Status (8)

Country Link
US (2) US7183400B1 (de)
EP (1) EP0980427B1 (de)
JP (1) JP2001512971A (de)
AT (1) ATE316574T1 (de)
DE (1) DE69833316T2 (de)
ES (1) ES2257804T3 (de)
FR (1) FR2759701B1 (de)
WO (1) WO1998037192A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807757B1 (fr) * 2000-04-18 2004-08-13 Inst Nat Sante Rech Med Nouvelle proteine ulip/crmp humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques et paraneoplastiques
FR2805540B1 (fr) * 2000-02-29 2004-04-09 Inst Nat Sante Rech Med Nouvelle proteine ulip humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
JP4990459B2 (ja) * 2000-02-29 2012-08-01 アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） 新規ヒトｕｌｉｐ／ｃｒｍｐタンパク質と癌及び傍新形成性神経症候群の診断及び治療におけるその使用
WO2002002620A2 (en) * 2000-06-29 2002-01-10 Mayo Foundation For Medical Education And Research Crmp-5 (collapsin response-mediator protein) encoding nucleic acid, polypeptide and uses thereof
ZA200204907B (en) 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
CA2461692A1 (fr) * 2001-09-07 2003-03-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire
FR2830762B1 (fr) * 2001-10-16 2004-10-22 Inst Nat Sante Rech Med Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire
FR2829392B1 (fr) * 2001-09-07 2005-09-16 Inst Nat Sante Rech Med Utilisation de crmps pour la fabrication d'un medicament destine a traiter les maladies liees a un dysfonctionnement du systeme immunitaire
US20120196307A1 (en) * 2007-02-06 2012-08-02 Banyan Biomarkers, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
CA2785431A1 (en) * 2009-07-16 2011-01-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Cleaved and phosphorylated crmp2 as blood marker of inflammatory diseases of the central nervous system
US20180117114A1 (en) * 2015-03-25 2018-05-03 Indiana University Research And Technology Coporation Peptides that modulate the effect of the crmp: neurofibromin complex on synaptic transmission
EP3564670A1 (de) * 2018-05-03 2019-11-06 Hospices Civils de Lyon Antikörper gegen trim9 und/oder trim67 in paraneoplastischen neurologischen syndromen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
ZA94845B (en) * 1993-02-09 1994-11-11 Univ Monash Methods for the diagnosis of diabetes and prediabetic conditions
US5723343A (en) * 1995-08-28 1998-03-03 University Of Florida Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor

Also Published As

Publication number Publication date
EP0980427A1 (de) 2000-02-23
EP0980427B1 (de) 2006-01-25
US7183400B1 (en) 2007-02-27
FR2759701B1 (fr) 1999-06-04
DE69833316T2 (de) 2006-09-28
US20070117166A1 (en) 2007-05-24
JP2001512971A (ja) 2001-08-28
ES2257804T3 (es) 2006-08-01
DE69833316D1 (de) 2006-04-13
WO1998037192A1 (fr) 1998-08-27
FR2759701A1 (fr) 1998-08-21

Similar Documents

Publication Publication Date Title
ATE302414T1 (de) Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
ATE316574T1 (de) Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
ID28971A (id) Turunan 2-ureido-tiazol, proses pembuatannya, dan penggunaannya sebagai zat anti tumor
DE69316948D1 (de) Lösliche Liganden für CD40
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
TR199501441A2 (tr) Islevsel poliorganosiloksanlar ve bunlarin hazirlanmasina mahsus islemlerden bir tanesi.
BG101077A (bg) Пептиди
TR199802423T2 (xx) Konsantre antikor terkibi.
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
DE60223547D1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
NL190399B (nl) Ijzer-bevattend eiwitmateriaal, bereiding daarvan, en farmaceutisch preparaat voor de behandeling van sideropene anaemie.
PT809437E (pt) Tiois para promover crescimento de celulas progenitoras hematopoieticas
DE69534325D1 (de) Peptide zur behandlung von krebs
ATE325803T1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties